RT Journal Article
SR Electronic
T1 Hospitalization time and outcome in patients with Coronavirus Disease 2019 (COVID-19): analysis data from China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.11.20061465
DO 10.1101/2020.04.11.20061465
A1 Chai, Songshan
A1 Xiao, Dongdong
A1 Cheng, Qikai
A1 Huang, Shengzhi
A1 Wang, Yihao
A1 Qian, Jiajia
A1 Wang, Jiajing
A1 Li, Junjun
A1 Fu, Peng
A1 Wang, Qiangping
A1 Rao, Jing
A1 Zhao, Hongyang
A1 Zhang, Fangcheng
A1 Xiong, Nanxiang
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.04.11.20061465.abstract
AB Objective The mean hospitalization time and outcome among patients with coronavirus disease 2019 (COVID-19) was estimated with the purpose of providing evidence for decision-making in medical institutions and governments in epidemic areas.Method The data of COVID-19 patients in china were collected from the websites of provincial and municipal health commissions. The mean hospitalization time and mortality in the mild or severe patients and the mean time from severe to mild illness were calculated by Gaussian mixture modeling.Results The mean hospitalization time among mild patients in Hubei province, other areas except Hubei province, and the national areas was 20.71± 9.30, 16.86 ± 8.24, and 19.34 ± 9.29 days, respectively. The mean transition time from severe to mild group in the above three areas were 15.00, 17.00, and 14.99 days, respectively. The death rate of mild and severe patients in Hubei province and the national areas were 1.10% and 18.14%, and 1.10% and 17.70%, respectively. Among those patients who died of COVID-19, the mean time from severe transition to death in Hubei province and the national areas was 6.22 ± 5.12 and 6.35 ± 5.27 days, respectively.Conclusion There were regional differences in the average length of stay between Hubei province and other regions, which may be related to different medical configurations. For those severe patients who died of COVID-19, the average time from hospitalization to death was about one week, and proper and effective treatments in the first week were critical.Competing Interest StatementThe authors have declared no competing interest.Funding StatementHubei Province Technical Innovation Special Soft Science Research Project (2019ADC034)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw/processed data required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study.